Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2018 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Leuk Res. 2018 Aug;71:82-88. doi: 10.1016/j.leukres.2018.06.014. Epub 2018 Jun 30.
Leuk Res. 2018.
PMID: 30025280
Clinical Trial.
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Verstovsek S, Mesa RA, Salama ME, Li L, Pitou C, Nunes FP, Price GL, Giles JL, D'Souza DN, Walgren RA, Prchal JT.
Verstovsek S, et al.
Leuk Res. 2017 Oct;61:89-95. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31.
Leuk Res. 2017.
PMID: 28934680
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite